LEK-8822, also known as 9,10-dihydro-LEK-8842 or as 9,10-dihydro-N-methyl-N-(2-propynyl)lysergamide, is a monoamine receptor modulator of the lysergamide family related to 9,10-dihydro-LSD. It is the analogue of LEK-8842 in which the double bond between the 9 and 10 positions of the ergoline ring system has been dihydrogenated. The drug is a partial agonist of α-adrenergic receptors, with considerably reduced potency and efficacy compared to LEK-8842. Due to this action, LEK-8822 can produce vasoconstriction. In addition to its α-adrenergic receptor activity, LEK-8822 shows preserved affinity for but elimination of agonist activity at serotonin 5-HT2 receptors compared to LEK-8842. LEK-8822 was first described in the scientific literature by 1992. It was developed by the Slovenian pharmaceutical company LEK Pharmaceuticals.
See also Substituted lysergamide LEK-8842 (9,10-didehydro-LEK-8822) LEK-8841 (2-bromo-LEK-8842) LEK-8829 (desoxy-LEK-8842) 9,10-Dihydro-LSD
References


